

## Corrigendum

# MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

**J Ryan<sup>1,2</sup>, A Tivnan<sup>1,2</sup>, J Fay<sup>1,2</sup>, K Bryan<sup>1,2</sup>, M Meehan<sup>1,2</sup>, L Creevey<sup>1,2</sup>, J Lynch<sup>1,2</sup>, IM Bray<sup>1,2</sup>, A O'Meara<sup>2</sup>, L Tracey<sup>3</sup>, AM Davidoff<sup>3</sup> and RL Stallings<sup>1,2</sup>**

<sup>1</sup>Department of Molecular and Cellular Therapeutics, Cancer Genetics Research Group, Royal College of Surgeons in Ireland (RCSI), York House, York Street, Dublin 2, Ireland; <sup>2</sup>National Children's Research Centre (NCRC), Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland; <sup>3</sup>Department of Surgery, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA

British Journal of Cancer (2012) **107**, 1203. doi:10.1038/bjc.2012.425 www.bjcancer.com  
© 2012 Cancer Research UK

**Correction to:** *British Journal of Cancer* (2012) **107**, 967–976.  
doi:10.1038/bjc.2012.356

The authors and publishers are now happy to present the complete, full authorship above.

Upon publication online and in print, the authors realised that a contributor to the original data for this manuscript had been omitted from the authorship of the final paper.